Tsc2 expression increases the susceptibility of renal tumor cells to apoptosis

Toxicological Sciences

Volumn 88, Issue 2, 2005, Pages 331-339

  Kolb, Todd M ^a   Duan, Ling ^a   Davis, Myrtle A ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Apoptosis; Okadaic acid; Tsc2; Tumorigenesis

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; GUANOSINE TRIPHOSPHATASE; OKADAIC ACID; POLYCYSTIN 1; TUBERIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ADHESION; CONTROLLED STUDY; GENE EXPRESSION; KIDNEY TUMOR; NONHUMAN; REGULATORY MECHANISM; TUMOR CELL;

ANIMALS; APOPTOSIS; CARCINOMA, RENAL CELL; CASPASE 3; CASPASES; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHROMONES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; KIDNEY NEOPLASMS; MORPHOLINES; OKADAIC ACID; RATS; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA;

EID: 27944446526     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfi310     Document Type: Article

References (47)

1. Astrinidis, A., Cash, T. P., Hunter, D. S., Walker, C. L., Chernoff, J., and Henske, E. P. (2002). Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration. Oncogene 21, 8470-8476.
2. Blume-Jensen, P., and Hunter, T. (2001). Oncogenic kinase signalling. Nature 411, 355-365.
3. Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., and Greenberg, M. E. (1999). Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857-868.
4. Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., and Reed, J. C. (1998). Regulation of cell death protease caspase-9 by phosphorylation. Science 282, 1318-1321.
5. Carsillo, T., Astrinidis, A., and Henske, E. P. (2000). Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc. Natl. Acad. Sci. U.S.A. 97, 6085-6090.
6. Cook, J. A., Oliver, K., Mueller, R. F., and Sampson, J. (1996). A cross sectional study of renal involvement in tuberous sclerosis. J. Med. Genet. 33, 480-484.
7. Dan, H. C., Sun, M., Yang, L., Feldman, R. I., Sui, X. M., Ou, C. C., Nellist, M., Yeung, R. S., Halley, D. J., Nicosia, S. V., et al. (2002). Phosphatidylinositol 3-kinase/Akt pathway regulates tuberous sclerosis tumor suppressor complex by phosphorylation of tuberin. J. Biol. Chem. 277, 35364-35370.
8. Datta, S. R., Brunet, A., and Greenberg, M. E. (1999). Cellular survival: A play in three Akts. Genes Dev. 13, 2905-2927.
9. Davis, M. A., and Carbott, D. E. (1999). Herbimycin A and geldanamycin inhibit okadaic acid-induced apoptosis and p38 activation in NRK-52E renal epithelial cells. Toxicol. Appl. Pharmacol. 161, 59-74.
10. Davis, M. A., Chang, S. H., and Trump, B. F. (1996). Differential sensitivity of normal and H-ras oncogene-transformed rat kidney epithelial cells to okadaic acid-induced apoptosis. Toxicol. Appl. Pharmacol. 141, 93-101.
11. Davis, M. A., Smith, M. W., Chang, S. H., and Trump, B. F. (1994). Characterization of a renal epithelial cell model of apoptosis using okadaic acid and the NRK-52E cell line. Toxicol. Pathol. 22, 595-605.
12. European Chromosome 16 Tuberous Sclerosis Consortium (1993). Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75, 1305-1315.
13. Evan, G. I., and Vousden, K. H. (2001). Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342-348.
14. Everitt, J. I., Goldsworthy, T. L., Wolf, D. C., and Walker, C. L. (1992). Hereditary renal cell carcinoma in the Eker rat: A rodent familial cancer syndrome. J. Urol. 148, 1932-1936.
15. Everitt, J. I., Goldsworthy, T. L., Wolf, D. C., and Walker, C. L. (1995). Hereditary renal cell carcinoma in the Eker rat: A unique animal model for the study of cancer susceptibility. Toxicol. Lett. 82-83, 621-625.
16. Gao, X., Zhang, Y., Arrazola, P., Hino, O., Kobayashi, T., Yeung, R. S., Ru, B., and Pan, D. (2002). Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat. Cell Biol. 4, 699-704.
17. Goncharova, E. A., Goncharov, D. A., Eszterhas, A., Hunter, D. S., Glassberg, M. K., Yeung, R. S., Walker, C. L., Noonan, D., Kwiatkowski, D. J., Chou, M. M., et al. (2002). Tuberin Regulates p70 S6 Kinase Activation and Ribosomal Protein S6 Phosphorylation. A Role for the TSC2 Tumor Suppressor Gene in Pulmonary Lymphangioleiomyomatosis (LAM). J. Biol. Chem. 277, 30958-30967.
18. Harada, H., Andersen, J. S., Mann, M., Terada, N., and Korsmeyer, S. J. (2001). p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD, Proc. Natl. Acad. Sci. U.S.A. 98, 9666-9670.
19. Henry, K. W., Yuan, X., Koszewski, N. J., Onda, H., Kwiatkowski, D. J., and Noonan, D. J. (1998). Tuberous sclerosis gene 2 product modulates transcription mediated by steroid hormone receptor family members. J. Biol. Chem. 273, 20535-20539.
20. Hino, O., Klein-Szanto, A. J., Freed, J. J., Testa, J. R., Brown, D. Q., Vilensky, M., Yeung, R. S., Tartof, K. D., and Knudson, A. G. (1993a). Spontaneous and radiation-induced renal tumors in the Eker rat model of dominantly inherited cancer. Proc. Natl. Acad. Sci. U.S.A. 90, 327-331.
21. Hino, O., Mitani, H., and Knudson, A. G. (1993b). Genetic predisposition to transplacentally induced renal cell carcinomas in the Eker rat. Cancer Res 53, 5856-5858.
22. Horesovsky, G., Ginsler, J., Everitt, J., and Walker, C. (1994). Increased susceptibility to in vitro transformation of cells carrying the Eker tumor susceptibility mutation. Carcinogenesis 15, 2183-2187.
23. Howe, S. R., Gottardis, M. M., Everitt, J. I., Goldsworthy, T. L., Wolf, D. C., and Walker, C. (1995). Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am. J. Pathol 146, 1568-1579.
24. Inoki, K., Li, Y., Zhu, T., Wu, J., and Guan, K. L. (2002). TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4, 648-657.
25. Jin, F., Wienecke, R., Xiao, G. H., Maize, J. C., Jr., DeClue, J. E., and Yeung, R. S. (1996). Suppression of tumorigenicity by the wild-type tuberous sclerosis 2 (Tsc2) gene and its C-terminal region. Proc. Natl. Acad. Sci. U.S.A. 93, 9154-9159.
26. Kenerson, H. L., Aicher, L. D., True, L. D., and Yeung, R. S. (2002). Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res. 62, 5645-5650.
27. Kleymenova, E., Ibraghimov-Beskrovnaya, O., Kugoh, H., Everitt, J., Xu, H., Kiguchi, K., Landes, G., Harris, P., and Walker, C. (2001). Tuberin-dependent membrane localization of polycystin-1: A functional link between polycystic kidney disease and the TSC2 tumor suppressor gene. Mol. Cell 7, 823-832.
28. Kolb, T. M., Chang, S. H., and Davis, M. A. (2002). Biochemical and morphological events during okadaic acid-induced apoptosis of Tsc2-null ERC-18 cell line. Toxicol. Pathol. 30, 235-246.
29. Kolb, T. M., and Davis, M. A. (2004). The tumor promoter 12-O-tetradecanoylphorbol 13-acetate (TPA) provokes a prolonged morphologic response and ERK activation in Tsc2-null renal tumor cells. Toxicol. Sci. 80, 233-242.
30. Laemmli, U. K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680-685.
31. Lau, S. S., Monks, T. J., Everitt, J. I., Kleymenova, E., and Walker, C. L. (2001). Carcinogenicity of a nephrotoxic metabolite of the "nongenotoxic" carcinogen hydroquinone. Chem. Res. Toxicol. 14, 25-33.
32. Momose, S., Kobayashi, T., Mitani, H., Hirabayashi, M., Ito, K., Ueda, M., Nabeshima, Y., and Hino, O. (2002). Identification of the coding sequences responsible for Tsc2-mediated tumor suppression using a transgenic rat system. Hum. Mol. Genet. 11, 2997-3006.
33. Noonan, D. J., Lou, D., Griffith, N., and Vanaman, T. C. (2002). A calmodulin binding site in the tuberous sclerosis 2 gene product is essential for regulation of transcription events and is altered by mutations linked to tuberous sclerosis and lymphangioleiomyomatosis. Arch. Biochem. Biophys. 398, 132-140.
34. Potter, C. J., Pedraza, L. G., and Xu, T. (2002). Akt regulates growth by directly phosphorylating Tsc2, Nat. Cell Biol. 4, 658-665.
35. Soucek, T., Pusch, O., Wienecke, R., DeClue, J. E., and Hengstschlager, M. (1997). Role of the tuberous sclerosis gene-2 product in cell cycle control. Loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase. J. Biol. Chem. 272, 29301-29308.
36. Soucek, T., Yeung, R. S., and Hengstschlager, M. (1998). Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc. Natl. Acad Sci. U.S.A. 95, 15653-15658.
37. Tee, A. R., Fingar, D. C., Manning, B. D., Kwiatkowski, D. J., Cantley, L. C., and Blenis, J. (2002). Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc. Natl. Acad. Sci. U.S.A. 99, 13571-13578.
38. Todd, D., Yang, G., Brown, R. W., Cao, J., D'Agati, V., Thompson, T. S., and Truong, L. D. (1996). Apoptosis in renal cell carcinoma: Detection by in situ end-labeling of fragmented DNA and correlation with other prognostic factors. Hum. Pathol. 27, 1012-1017.
39. Tsuchiya, H., Orimoto, K., Kobayashi, K., and Hino, O. (1996). Presence of potent transcriptional activation domains in the predisposing tuberous sclerosis (Tsc2) gene product of the Eker rat model. Cancer Res. 56, 429-433.
40. van Slegtenhorst, M., Nellist, M., Nagelkerken, B., Cheadle, J., Snell, R., van den Ouweland, A., Reuser, A., Sampson, J., Halley, D., and van der Sluijs, P. (1998). Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum. Mol. Genet. 7, 1053-1057.
41. Walker, C., Goldsworthy, T. L., Wolf, D. C., and Everitt, J. (1992). Pre-disposition to renal cell carcinoma due to alteration of a cancer susceptibility gene. Science 255, 1693-1695.
42. Wienecke, R., Konig, A., and DeClue, J. E. (1995). Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity. J. Biol. Chem. 270, 16409-16414.
43. Wolf, D. C., Goldsworthy, T. L., Donner, E. M., Harden, R., Fitzpatrick, B., and Everitt, J. I. (1998). Estrogen treatment enhances hereditary renal tumor development in Eker rats. Carcinogenesis 19, 2043-2047.
44. Xiao, G. H., Shoarinejad, F., Jin, F., Golemis, E. A., and Yeung, R. S. (1997). The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis. J. Biol. Chem. 272, 6097-6100.
45. Yu, J., Astrinidis, A., and Henske, E. P. (2001). Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. Am. J. Respir. Crit. Care Med. 164, 1537-1540.
46. Zha, J., Harada, H., Yang, E., Jockel, J., and Korsmeyer, S. J. (1996). Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87, 619-628.
47. Zhang, Y., Gao, X., Saucedo, L. J., Ru, B., Edgar, B. A., and Pan, D. (2003). Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol. 5, 578-581.